↓ Skip to main content

Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer

Overview of attention for article published in Investigational New Drugs, March 2010
Altmetric Badge

Mentioned by

policy
1 policy source

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
41 Mendeley
Title
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Published in
Investigational New Drugs, March 2010
DOI 10.1007/s10637-010-9413-7
Pubmed ID
Authors

Colin D. Weekes, Sujatha Nallapareddy, Michelle A. Rudek, Alexis Norris-Kirby, Daniel Laheru, Antonio Jimeno, Ross C. Donehower, Kathleen M. Murphy, Manuel Hidalgo, Sharyn D. Baker, Wells A. Messersmith

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Unknown 40 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 20%
Researcher 5 12%
Student > Doctoral Student 4 10%
Professor > Associate Professor 4 10%
Student > Master 3 7%
Other 6 15%
Unknown 11 27%
Readers by discipline Count As %
Medicine and Dentistry 12 29%
Biochemistry, Genetics and Molecular Biology 4 10%
Nursing and Health Professions 4 10%
Agricultural and Biological Sciences 3 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 4 10%
Unknown 13 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2017.
All research outputs
#7,526,794
of 22,968,808 outputs
Outputs from Investigational New Drugs
#327
of 1,173 outputs
Outputs of similar age
#34,729
of 95,127 outputs
Outputs of similar age from Investigational New Drugs
#2
of 9 outputs
Altmetric has tracked 22,968,808 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,173 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,127 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.